All In Biotech

Drug Trial Radar · NCT00829192

Phase II AK Study in Organ Transplant Patients

A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.

Last checked: Nov 20, 2026Latest source record: Dec 6, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 2007

Primary completion

Jul 2012

Study completion Aug 2012

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in reducing the number of actinic keratoses and squamous cell carcinomas developing in immune compromised organ transplant recipients, who are at particularly high risk, over a 24 month test period. The number of lesions formed on the head, hands and forarms will be monitored over this 24 month test period.

Conditions

  • Actinic Keratoses
  • Carcinoma, Squamous Cell
  • Organ Transplant Recipients

Interventions

  • Afamelanotide (CUV1647)Drug

    16 mg subcutaneous implant administered every 60 days

  • PlaceboDrug

    Placebo subcutaneous implant administered every 60 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the effect of afamelanotide (CUV1647) administered from slow release subcutaneous implants on the number of actinic keratoses (AKs) on the head, forearms and back of handsTime frame: 24 months

Locations

12 sites in 7 countries. Site status is shown where the registry gives one.

  • The Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • The Queen Elizabeth Hospital

    Adelaide, South Australia, Australia

  • The Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Hospital Erasme

    Brussels, Belgium

  • Gent University Hospital

    Ghent, Belgium

  • University Hospital

    Besançon, France

  • Charité Univeritätsklinikum

    Berlin, Germany

  • Kiel University Hospital

    Kiel, Germany

  • Ospedali Riuniti di Bergamo

    Bergamo, Italy

  • University of Padua

    Padua, Italy

  • Karolinska University Hospital

    Stockholm, Sweden

  • Universitätsspital Zürich

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.